Valuation dashboard for Grace Therapeutics, Inc. (GRCE) with P/E N/A, P/B 0.75, EV/EBITDA -0.80 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $2.14, GRCE has negative trailing earnings (P/E not meaningful) and an ROE of -35.78%. Market capitalisation stands at $35M.
Balance sheet quality for GRCE: current ratio of 8.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.75 |
| EV / EBITDA | -0.80 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.71 |
| vs Current Price | -66.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | $35M | 0.75 | -35.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.14 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -35.78% |
| Return on Invested Capital | -48.75% |
| Return on Assets | -42.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABVC · ATNM · CALC · LTRN · LVTX · OKUR · PDSB
Explore sector: Healthcare · Biotechnology
More sections of GRCE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks